International Flavors & Fragrances
IFFBusiness Overview
ticker: IFF step: 01 generated: 2026-05-13 source: quick-research
International Flavors & Fragrances Inc. (IFF) — Business Overview
Business Description
International Flavors & Fragrances is a global specialty chemicals company that creates ingredients for taste, scent, nutrition, and functional ingredients across food & beverage, personal care, home care, and health sectors. IFF was dramatically expanded via the 2021 merger with DuPont's Nutrition & Biosciences division, roughly tripling revenue but saddling the company with ~$12B+ in debt. Since then, IFF has been restructuring — divesting non-core assets ($1.3B in divestitures including the Pharma Solutions segment sold to Roquette for $2.85B, completed May 2025) and deleveraging toward a focused, higher-margin specialty chemicals business.
Revenue Model
Revenue is generated through direct sales of flavor, fragrance, and functional ingredient solutions to global food & beverage companies, personal care brands, and institutional buyers. Long-term supply relationships with consumer staples majors (Unilever, P&G, Nestlé, Coca-Cola) provide revenue visibility. Pricing incorporates raw material pass-throughs and value-based premiums for proprietary formulations. FY2024 revenue: $11.5B.
Products & Services
- Taste: Flavors for food & beverages (~$2.5B annualized); savory, sweet, beverage flavors
- Food Ingredients: Proteins, starches, probiotics, cultures, enzymes for food applications (segment being explored for sale)
- Scent: Fragrances for personal care and home care brands (~$2.5B annualized)
- Pharma Solutions: Excipients for drug delivery (sold to Roquette for $2.85B, completed May 2025)
- Health & Biosciences: (integrated into other segments post-restructuring)
Customer Base & Go-to-Market
Serves global consumer goods companies (Unilever, P&G, Coca-Cola, Nestlé, Mondelez) and pharmaceutical manufacturers. Long-term contracts with formulation-specific ingredients create switching costs — once a flavor or fragrance is approved in a product, changing supplier requires re-qualification. This "lock-in" dynamic provides revenue durability even in soft demand environments.
Competitive Position
IFF competes with Givaudan, Firmenich (now merged as Givaudan), Symrise, and Sensient Technologies. Givaudan is the global leader with ~25% market share; IFF is #2 at ~15-20%. The taste/scent market is oligopolistic — the top 3 players control 60%+ of global flavor/fragrance sales, enabling pricing discipline. IFF's scale advantage post-N&B merger is significant but was acquired at a high price that left the balance sheet leveraged.
Key Facts
- Founded: 1958
- Headquarters: New York, NY
- Employees: ~22,000
- Exchange: NYSE
- Sector / Industry: Materials / Specialty Chemicals
- Market Cap: ~$14B
Financial Snapshot
ticker: IFF step: 04 generated: 2026-05-13 source: quick-research
International Flavors & Fragrances Inc. (IFF) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $12.44B | $11.48B | $11.48B | ~flat |
| Gross Margin | ~35% | ~35% | ~36% | |
| Operating Margin | ~5% | ~-5% (impairments) | ~7% | |
| Net Income | ~$500M | ~-$2.5B (write-downs) | ~$250M | |
| EPS (diluted) | ~$2.00 | ~-$10.00 (non-cash) | ~$1.00 |
FY2023 GAAP net loss driven by large non-cash goodwill impairments on the 2021 N&B acquisition — not reflective of operating performance. Adjusted EBITDA is the more relevant metric: ~$2.0B in FY2024 (target: $2.0-2.15B in 2025). Q1 2025 revenue: $2.84B.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Free Cash Flow | $607M |
| Capital Expenditures | $1.07B (elevated; normalizing) |
| Adjusted EBITDA | ~$2.0B |
| Total Debt | ~$10B+ (post-N&B merger) |
| Net Debt / EBITDA | ~3.0x (target: <3x post-divestitures) |
Key Ratios (approximate)
- P/E: ~20x (adj.) | EV/EBITDA: ~10x | FCF Yield: ~4%
- Revenue Growth (FY2024): ~flat | Adj. EBITDA Margin: ~17%
- Fitch upgrade to 'BBB' (investment grade) after debt reduction
Growth Profile
IFF is in a multi-year restructuring phase following the overpriced 2021 N&B acquisition (~$26B). Revenue has been flat as divestitures and weak organic growth offset each other. The $2.85B Pharma Solutions sale (completed May 2025) and ongoing Food Ingredients exploration provide deleveraging capital. FY2025 guidance: revenue $10.6-10.9B (lower, reflecting Pharma Solutions divestiture) with adjusted EBITDA $2.0-2.15B — EBITDA margin expansion is the core recovery story.
Forward Estimates
- FY2026 Guidance: 1-4% sales growth; 3-8% EBITDA growth; net debt/EBITDA target <2.5x
- Analyst avg. price target: ~$83-99 (JPMorgan $92, Citi $96)
- Return on capital improvement: from 2.77% to 5.32% over last 12 months; projected 6.37%
- Capital allocation: $1.2B debt tender completed; revolving credit facility undrawn ($2B capacity)
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $IFF.